Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2015-01-16 Capital/Financing Update
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC, dated January 16, 2015, for Zafgen, Inc. It is a preliminary prospectus related to a securities offering, including details about the offering, underwriting, risk factors, and company overview. The document is a registration statement amendment under the Securities Act of 1933, which is a capital markets filing related to the company's fundraising and securities issuance. This type of document is classified as a Capital/Financing Update (CAP) because it pertains to the registration and offering of securities to the public, not an annual report, earnings release, or other report types. The document length is substantial (15,000 characters), and it contains detailed offering information, underwriting, and risk disclosures typical of a registration statement amendment.
2015-01-16 English
FORM 4 SUBMISSION
Director's Dealing
2015-01-12 English
FORM 4 SUBMISSION
Director's Dealing
2015-01-12 English
FORM 4 SUBMISSION
Director's Dealing
2015-01-12 English
FORM 4 SUBMISSION
Director's Dealing
2015-01-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a press release about Phase 2 clinical trial results, filed as an exhibit. The document is short (2419 characters) and primarily serves as an announcement of an event and a press release, not a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed governance information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-01-12 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.